Liprotamase - Alkira Therapeutics

Drug Profile

Liprotamase - Alkira Therapeutics

Alternative Names: ALTU-135; Liprotamase; LY-3031642; Sollpura; TheraCLEC™-Total; Trizytek™

Latest Information Update: 09 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics
  • Developer Anthera Pharmaceuticals; Cystic Fibrosis Foundation Therapeutics
  • Class Amylases; Carboxylic ester hydrolases; Pancreatic enzymes; Peptide hydrolases
  • Mechanism of Action Amylase replacements; Lipase replacements; Peptide hydrolase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Exocrine pancreatic insufficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Exocrine pancreatic insufficiency

Most Recent Events

  • 28 Mar 2018 Anthera Pharmaceuticals has 4 European patents and 16 non-European issued patents for liprotamase
  • 12 Mar 2018 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In adolescents, In children, In infants, In adults) in USA (PO) (NCT02823964)
  • 12 Mar 2018 Discontinued - Phase-III for Exocrine pancreatic insufficiency (In adolescents, In children, In the elderly, In adults) in USA, United Kingdom, Spain, Poland, Lithuania, Israel, Hungary (PO) (NCT03051490)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top